We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Benchtop Technology Designed for Marking, Selecting Cells

By LabMedica International staff writers
Posted on 22 Jan 2013
Chemists have found a simpler way to perform one of the most essential chores in molecular biology. More...
Their new method allows scientists to add a marker to specific cells, so that these cells may be easily located and/or chosen from a larger cell population.

The technique, which is described in January 2012 in the chemistry journal Angewandte Chemie International Edition, makes use of the tight binding of two proteins that are inexpensively available but are not found in human or other mammalian cells. Therefore, it has advantages over existing cell-marking techniques.

“This new technique is cheap, easy, and sensitive,” said the Scripps Research Institute (TSRI; La Jolla, CA, USA) Prof. Richard A. Lerner, who is the senior author of the new report. “The method should be useful in a variety of applications that require separating out certain types of cells.”

The best-known cell marker currently used is green fluorescent protein (GFP), a protein derived from a jellyfish that emits a characteristic green light when illuminated by specific light wavelengths. When scientists need to add a new gene to cells, for example, to produce a therapeutic protein, they frequently construct a genetic sequence that also includes the GFP gene. Consequently, the cells that effectively produce the new protein will also generate GFP, whose fluorescence allows these cells to be identified and even sorted out from a larger population.

However, fluorescence-based cell sorting is comparatively costly and cumbersome. Alternative cell-marking techniques use marker molecules to which metals or antibodies will bind tightly, but these tend to have annoying side effects on the cells that they mark. Prof. Lerner’s team, led by first author Yingjie Peng, a postdoctoral fellow, set out to devise a better approach.

The new method exploits a special characteristic of chitinase enzymes, which evolved degrade chitin—a rugged, sugar-derived substance found, for example, in squid beaks, crab shells, and the cell walls of fungi. In addition to a main chitin-breaking domain, chitinases have another active structure, a chitin-binding domain (ChBD). “It makes a super-strong bond with chitin,” said Dr. Peng. Recently, scientists have begun to use this high-affinity binding of ChBD and chitin as a marker system, typically for selecting ChBD-tagged proteins in a lab dish. The new method uses ChBD to mark and select cells.

A new gene, in the method, can be added to cells within a larger DNA vector that also includes the genetic sequences for ChBD and GFP. The ChBD molecule will be produced in such a way that it ends up being held on the outer surface of its host cell’s plasma membrane—and the GFP molecule will sit just inside the membrane. The GFP acts as a visual beacon, while the ChBD serves as a handy gripping point for cell selection.

The scientists, after exposing a culture of test cells to this research ChBD-containing vector, were able to visualize, by way of the GFP tags, which cells were expressing them, and was able to pick them out easily, with high sensitivity, utilizing magnetic beads coated with chitin. “This is a relatively easy benchtop method,” Dr. Peng said. Significantly, these selected cells could generate progeny cells that appeared healthy.

Because the ChBD marker, in the vector, is produced in a manner that secures it to a cell’s membrane, it also can serve as a vital application for selecting just the membrane fraction of a sample of cellular material. Dr. Peng and his colleagues showed this using chitin beads to rapidly isolate a pure fraction of membrane material from ChBD-marked test cells. Cellulase enzymes, which degrade the common plant compound cellulose, also have a high-affinity cellulase-binding domain, which can be employed in the same way as the ChBD.

The scientists expect that the new cell-marking method will help to streamline another major molecular biology technique, which was developed by the Lerner laboratory in parallel with the group of Sir Gregory Winter at the Laboratory of Molecular Biology (Cambridge, UK). This technique allows scientists to produce very large and diverse libraries of antibody arms, and to sift through them, or “pan”—in the way miners pan for gold nuggets—for those that might be of use, for example in therapies. ChBD-based markers should be beneficial in boosting the effectiveness of this panning process, according to Dr. Peng.

The investigators are also assessing the potential use of ChBD-based cell marking in living animals, for example, to monitor the outcome of selected cell types throughout an animal’s lifecycle.

Related Links:
Scripps Research Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.